Boston Life Sciences Announces Expansion of Clinical, Regulatory and Patent Departments.

Business Editors and Health/Medical Writers

BOSTON--(BUSINESS WIRE)--Nov. 20, 2001

Clinical Directors in Neuroimaging, CNS Therapeutics and Cancer,

as well as Directors of Regulatory and Patent Affairs added to meet

needs of clinical development programs

Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that the Company had recently hired three new Clinical Directors specializing in the Company's clinical development areas as well as a Director of Regulatory Affairs to lead the Company's regulatory filing processes in each of these areas. In addition, the growing patent portfolio derived from the ongoing collaborations with Harvard Medical School and its affiliated hospitals is now being managed by in-house Patent Counsel. The Company has also hired clinical associates in each of these areas to assist the Directors in planning and managing the upcoming clinical trials.

In Neuro-imaging Diagnostics, the Company has hired Dr. Robert Licho, presently an Assistant Professor of Nuclear Medicine, University of Massachusetts Medical Center. Dr. Licho is an expert in SPECT imaging and was a Principal Investigator in the Company's Altropane Parkinson's Disease and ADHD clinical trials. Dr. Licho is directing the Company's Altropane Phase II clinical trials in both children and adults for the diagnosis of ADHD.

In CNS Therapeutics, the Company has hired Dr. Marie-Louise Jacques to direct the Company's clinical efforts using Inosine for the regenerative treatment for stroke and spinal cord injury, and the clinical development of the Company's Dopamine Transport (DAT) blockers to treat Parkinson's Disease and ADHD. Dr. Jacques was previously Head of International Clinical R&D (ex-US) at Novartis' ophthalmic division.

In Oncology, the Company has hired Dr. Lee Schacter, to direct the Company's anti-angiogenic program in oncology. Dr. Schacter is charged with designing and implementing the Phase I/II clinical study of Troponin as a preventative treatment for cancer metastases in high risk patients. Dr. Schacter was previously Senior Medical Director/Global Product Team Physician at Astra Zeneca and prior to that was Director, Clinical Cancer Research at Bristol Meyers Squibb.

The Company has hired Jeanne-Marie Varga as Director, Regulatory Affairs. Ms. Varga was previously Director, Regulatory Affairs at Baxter Healthcare Corp. and V.P. of Worldwide Regulatory affairs at Sanofi Diagnostics Pasteur, Inc. Prior to these Regulatory Affairs positions, Ms. Varga was a Senior Scientific Reviewer, Immunology Branch at the FDA. Ms. Varga is in charge of compiling and filing the Company's New Drug Application (NDA) for Altropane for the diagnosis of Parkinson's Disease, as well as all subsequent regulatory filings for the Company's products.

Dr. Leslie Levine has been hired as Director, Intellectual Property and Patent Affairs. Dr. Levine is a graduate of Harvard Law School and earned a PhD in Physiology from the University of Pennsylvania School of Medicine. Dr. Levine was previously Assistant General Counsel at Biogen, Inc. and Director of Intellectual Property at Transkaryotic Therapies, Inc.

In addition to the Directors, the Company has expanded its team of Clinical Research Associates to assist the Directors in managing and implementing the individual clinical trials for each product in clinical development.

David Hillson, President and CEO of BSLI commented: "The maturation and transition of BLSI from a pre-clinical product development company to a company fully engaged in human clinical trials is reflected in these major additions to our professional staff. We have five human clinical trials on-deck for 2002, spread over phase I, II and III, as well as an NDA to be filed. The scientific basis for all this progress is detailed in numerous scientific publications produced by our collaborating scientists. It is the quality of this work that has enabled us to attract such a high-caliber team."

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: ALTROPANE(TM) and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.